| Group | Subgroup | Autoantibody positivity population (panel of 7) | ||||
| Stage I | Stage II | Stage III | Stage IV | |||
| SCLC | Number +ve | 0 | 0 | 2/3 | 7/11 | |
| n = 14 | % +ve (95% CI) | 67 (9 to 99) | 64 (31 to 89) | |||
| SCLC | Pre-Tx | Number +ve | 0 | 0 | 1/1 | 7/11 |
| n = 12 | % +ve (95% CI) | 100 (3 to 100) | 64 (31 to 89) | |||
| NSCLC | Number +ve | 4/5 | 4/4 | 10/13 | 21/27 | |
| n = 49 | % +ve (95% CI) | 80 (28 to 99) | 100 (40 to 100) | 77 (46 to 95) | 78 (58 to 91) | |
| NSCLC | Pre-Tx | Number +ve | 3/3 | 3/3 | 5/7 | 15/20 |
| n = 33 | % +ve (95% CI) | 100 (29 to 100) | 100 (29 to 100) | 71 (29 to 96) | 75 (51 to 91) | |
Number and percentage positivity (% +ve) with 95% confidence interval (95% CI) in each tumour stage (where known) using panel 1/7. Stage taken at diagnosis date follows from T,N,M-staging.
SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer; 95% CI denotes the 95% confidence interval; Pre-Tx, pretreatment samples.
Samples taken within 6 months of diagnosis for NSCLC, and within 4 months of diagnosis for SCLC.